Mr. Weisberg is leading PolyPid since 2010 and has 20 years of experience as an entrepreneur and CEO of start-up companies with two financial exits. Prior to PolyPid, Mr. Weisberg managed start-up companies in the Life Science sphere, from incubator stage to clinical trials, including leading the financing rounds for these companies.
Dr. Emanuel has vast experience in biotechnology projects, including development of drug delivery systems and immunology. His extensive expertise includes immunotherapy, vaccines, immunodiagnostics, systemic and local drug-delivery, and medical devices. Dr. Emanuel has a number of approved patents in the field of drug delivery and diagnostics. Dr. Emanuel is a co-founder of PolyPid and served as its CEO during the company’s first three years. He received his Ph.D. degree from the Faculty of Medicine at the Hebrew University of Jerusalem.
Mrs. Czaczkes Akselbrad spent over 12 years with Compugen the last 7 years of which as Chief Financial Officer where she played a leading role in numerous capital transactions raising over $130M. Before joining Compugen, Ms. Czaczkes Akselbrad was Chief Financial Officer of Packet Technologies Ltd., and an audit manager at Ernst & Young Israel. She holds an MBA in finance and a BA in accounting and economics, both from Tel Aviv University, and is a certified public accountant in Israel.
Dr. Gelvan is a seasoned healthcare executive with over twenty years of experience working with, managing and investing in life sciences companies. Until recently, Dr. Gelvan was Managing Director of Aurum Ventures where he was responsible for life science investments. In the past, Dr. Gelvan was founder and CEO of I2O Pharma and Zetiq Technologies and CEO of Gammacan International (OTCBB: GCAN) and Vecta Ltd. Dr. Gelvan holds a Ph.D. in Business Economics from RUC in Denmark and is an experienced lecturer in corporate finance and entrepreneurship.
Mr. Kyiet has 15 years’ experience holding a senior operations and business planning position in Biosense Webster (a Johnson & Johnson company), several business development and strategic alliance positions with Lumenis and also an M&A and high-tech partner in a major Tel Aviv law firm and an in-house counsel to a publicly-traded company in Israel and on NASDAQ. He holds an LL.B. in law and an MBA, both from Haifa university.
Dr. Blum is a pharmaceutical medicine specialist with 20 years’ experience in the development of Medicinal Products, from regulatory and clinical aspects to business development. Dr. Blum held various senior positions in Pharma, Biotech, Medical Devices and CRO companies both private and publically traded. As a serial entrepreneur Dr. Blum was founder and CEO of two Biomed and Biotech start-up companies. Dr. Blum holds an adjunct position of assistant professor in the Technion Faculty of Medicine, authored over 30 papers published in peer review journals and won prestigious prizes from the American College of Cardiology and the Israel Heart Society. Dr. Blum earned his MD and PhD degrees from the Technion, Israel Institute of Technology and a Diploma of Advanced Studies in Pharmaceutical Medicine from the University of Basel, Switzerland.
Dr. Alon has a broad leadership experience in business and technology development of healthcare and life science innovation from research to commercialization.
Prior to joining PolyPid, Dr. Alon served for six years as a Vice President of Business Development at Hadasit Medical Research Services & Development Ltd., the Technology Transfer Organization and commercial arm of Hadassah Medical Organization in Israel. Her expertise includes building value via partnering, licensing, venture development, financing and marketing of early stage innovative technologies. She has led R&D programs across therapeutic areas in Pharma and Biotech companies both in US & Israel. Dr. Alon holds a PhD, Summa Cum Laude, in Molecular Biology and an MBA both from the Hebrew University of Jerusalem. She was a postdoctoral research associate at the Rockefeller University in New York.
Dr. Zelikovich has more than 15 years of experience as a senior R&D leader in pharma and agro companies. Prior to joining PolyPid, Dr. Zelikovich was with Perrigo API (Chemagis) for 12 years, holding several positions, recently as director of process development, managing all chemical process development. Prior to that, Lior served as head of CMC in biopharmaceutical startup companies, and in the agro chemical industry. Dr. Zelikovich holds a PhD from Weizmann Institute in Organic Chemistry, and an MBA from Tel Aviv University. He has more than 15 scientific publications and patents.
Mrs. Cohen has over 8 years of experience in private Hi-Tech companies, such as Ramdor, HiClass and Eldor, fulfilling key positions in general administration, human resource management and recruitment. Ms. Cohen was also an assistant marketing manager of Beit Berl College. She holds a B.A. degree in Sociology and Anthropology from the Tel Aviv University.